2026-05-28T03:04:19Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/347242026-02-03T11:24:16Zcom_10630_2254col_10630_37953

El-Bekay, Rajaa Coín-Aragüez, Leticia I. Fernandez-García, Diego Oliva Olivera, Wilfredo Bernal-López, María Rosa Clemente-Postigo, María Mercedes Delgado-Lista, Javier Díaz-Ruiz, Alberto Guzmán-Ruiz, Rocio Vázquez-Martínez, Rafael Lhamyani, Said Roca-Rodríguez, María del Mar Fernández-Veledo, Sonia Vendrell, Joan Malagón, Maria M. Tinahones-Madueño, Francisco José 2024-10-14T09:29:23Z 2024-10-14T09:29:23Z 2016-03-18 https://hdl.handle.net/10630/34724 10.1111/bph.13481 Glucagon-like peptide-1 (GLP-1) analogues improve glycaemic control in type 2 diabetic (T2D) patients and cause weight loss in obese subjects by as yet unknown mechanisms. We recently demonstrated that the GLP-1 receptor, which is present in adipocytes and the stromal vascular fraction of human adipose tissue (AT), is up-regulated in AT of insulin-resistant morbidly obese subjects compared with healthy lean subjects. The aim of this study was to explore the effects of in vitro and in vivo administration of GLP-1 and its analogues on AT and adipocyte functions from T2D morbidly obese subjects. eng http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 Internacional Péptidos Obesidad - Aspectos moleculares Tejido adiposo Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes. journal article